

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	10/767,476
				Filing Date	01/28/2004
				First Named Inventor	Stuelpnagel et al.
				Art Unit	1639
				Examiner Name	Steele, Amber D.
Sheet	1	of	2	Attorney Docket Number	01-00008

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.*	Document Number/Kind Code*	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/ADS/	1	4,349,510	09/14/1982	Kolehmainen et al.	
	2	4,879,097	11/07/1989	Whitehead et al.	
	3	4,922,092	05/01/1990	Rushbrooke et al.	
	4	5,618,701	04/08/1997	Landegren	
	5	5,682,232	10/28/1997	Tajima et al.	
	6	5,784,152	07/21/1998	Heffelfinger et al.	
	7	5,800,922	09/01/1998	Fodor et al.	
	8	5,876,946	03/02/1999	Burbaum et al.	
	9	6,083,763	07/04/2000	Balch	
	10	6,191,852	02/20/2001	Paffhausen et al.	
/ADS/	11	6,327,410	12/04/2001	Walt et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.*	Foreign Patent Document Country Code*-Number*-Kind Code*	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
/ADS/	12	EP 0 269 764	06/08/1988	Molecular Biosystems, Inc.		
/ADS/	13	WO 89/11101	11/16/1989	Dynal A.S.		
/ADS/	14	EP 0 478 319	04/01/1992	Kabushiki Kaisha Toshiba		
/ADS/	15	WO 93/02360	02/07/1993	Trans-Med Biotech, Inc.		
/ADS/	16	WO 96/03212	02/08/1996	Sydney Brenner		
/ADS/	17	WO 97/14028	04/17/1997	Luminex Corp.		
/ADS/	18	WO 99/05320	02/04/1999	Rapigene, Inc.		

Examiner Signature	/Amber Steele/	Date Considered	05/15/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Applicant's unique citation designation number (optional). \* See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/767,476
				Filing Date	01/28/2004
				First Named Inventor	Stuelpnagel et al.
				Art Unit	1639
Examiner Name	Steele, Amber D.				
Sheet	2	of	2	Attorney Docket Number	01-00008

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ADS/	19	DRMANAC, R. et al., "Sequencing by Hybridization," Automated DNA Sequencing and Analysis, ed. M. Adams, C. Fields and J. Venter (1994).	
/ADS/	20	ILLUMINA INC., "Emerging," Windhover's In Vivo, The Business and Medicine Report, 1 - 2 (1998).	
/ADS/	21	ILLUMINA INC., Slides presented by Illumina at Cambridge Healthtech Institute's Implications of Human Genetic Variation - SNP's, Polymorphisms, Diseases & Treatment. November 18-19, 1998, Waltham, Massachusetts.	
/ADS/	22	POPE, E., "Fiber Optic Chemical Microsensors Employing Optically Active Silica Microspheres," SPIE Proc., 2388:245 - 256 (1995).	

Examiner Signature	/Amber Steele/	Date Considered	05/15/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450